Rongshan Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rongshan Yan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alan S. Verkman
University of California
1 shared publication - Asim Visal Farooq
Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL, United States
1 shared publication - Ethan S. Lindgren
Department of Ophthalmology, University of California San Francisco, San Francisco, USA
1 shared publication - Gerami D. Seitzman
Department of Ophthalmology, University of California, San Francisco, CA
1 shared publication - Hope S. Rugo
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
1 shared publication - Janice Lu
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
1 shared publication
Latest Publications
- Open Access
- 25 March 2024
- Published by Springer Nature in Current Ophthalmology Reports
- Vol. 12 (2) , 13-22
Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs)
Purpose of Review: This study is to highlight the incidence of corneal pseudomicrocysts in FDA-approved antibody–drug conjugates (ADCs), and success of preventive therapies for pseudomicrocysts and related ocular surface adverse events (AEs). Recent Findings: ADCs are an emerging class of selective cancer therapies that consist of a potent cytotoxin connected to a monoclonal antibody (mAb) that targets antigens expressed on malignant cells. Currently, there are 11 FDA-approved ADCs with over 164 in clinical trials. Various AEs have been attributed to ADCs, including ocular surface AEs (keratitis/keratopathy, dry eye, conjunctivitis, blurred vision, corneal pseudomicrocysts). While the severity and prevalence of ADC-induced ocular surface AEs are well reported, the reporting of corneal pseudomicrocysts is limited, complicating the development of therapies to prevent or treat ADC-related ocular surface toxicity. Summary: Three of 11 FDA-approved ADCs have been implicated with corneal pseudomicrocysts, with incidence ranging from 41 to 100% of patients. Of the six ADCs that reported ocular surface AEs, only three had ocular substudies to investigate the benefit of preventive therapies including topical steroids, vasoconstrictors, and preservative-free lubricants. Current preventive therapies demonstrate limited efficacy at mitigating pseudomicrocysts and other ocular surface AEs.
- 25 March 2024
- Published by Springer Nature in Current Ophthalmology Reports
- Vol. 12 (2) , 13-22
Open AccessIncidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs)
Purpose of Review: This study is to highlight the incidence of corneal pseudomicrocysts in FDA-approved antibody–drug conjugates (ADCs), and success of preventive therapies for pseudomicrocysts and related ocular surface adverse events (AEs). Recent Findings: ADCs are an emerging class of selective cancer therapies that consist of a potent cytotoxin connected to a monoclonal antibody (mAb) that targets antigens expressed on malignant cells. Currently, there are 11 FDA-approved ADCs with over 164 in clinical trials. Various AEs have been attributed to ADCs, including ocular surface AEs (keratitis/keratopathy, dry eye, conjunctivitis, blurred vision, corneal pseudomicrocysts). While the severity and prevalence of ADC-induced ocular surface AEs are well reported, the reporting of corneal pseudomicrocysts is limited, complicating the development of therapies to prevent or treat ADC-related ocular surface toxicity. Summary: Three of 11 FDA-approved ADCs have been implicated with corneal pseudomicrocysts, with incidence ranging from 41 to 100% of patients. Of the six ADCs that reported ocular surface AEs, only three had ocular substudies to investigate the benefit of preventive therapies including topical steroids, vasoconstrictors, and preservative-free lubricants. Current preventive therapies demonstrate limited efficacy at mitigating pseudomicrocysts and other ocular surface AEs.